In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper K, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.

Abstract

Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. Measurement of PD-L1 protein is limited by the lack of standardized immunohistochemical methods and variable performance of antibodies. Our goal was to correlate PD-L1 mRNA expression with clinical variables in primary breast carcinomas.

Experimental Design: The fluorescent RNAscope paired-primer assay was used to quantify in situ PD-L1 mRNA levels in 636 stage I–III breast carcinomas on two sets of tissue microarrays [YTMA128 (n = 238) and YTMA201 (n = 398)]. Tumor-infiltrating lymphocytes (TIL) were assessed by hematoxylin/eosin stain and quantitative fluorescence.

Similar Articles

Role of altered expression of HLA class I molecules in cancer progression

Author(s): Aptsiauri N, Cabrera T, Mendez R, Garcia-Lor A, Ruiz-Cabello F, et al.

β-Arrestin-dependent, G protein-independent ERK1/2 activation by the 2-adrenergic receptor

Author(s): Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al.

Human T cell responses against melanoma

Author(s): Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P

Mutations in GNA11 in Uveal Melanoma

Author(s): Van Raamsdonk C, Griewank K, Michelle B, Crosby MB, Garrido MC, et al.

Cohesin‐SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres

Author(s): Remeseiro S, Cuadrado A, Carretero M, Martínez P, Drosopoulos WC, et al.

MDM4 is a key therapeutic target in cutaneous melanoma

Author(s): Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele A, et al.

Epithelial–mesenchymal transition in cancer development and its clinical significance

Author(s): Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al.

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

Author(s): Kokkola R, Andersson A, Mullins G, Östberg T, Treutiger CJ, et al.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Author(s): Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al.

The epithelial-mesenchymal transition generates cells with properties of stem cells

Author(s): Mani A, Guo W, Liao MJ, Eaton E, Ayyanan A, et al.

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Author(s): Azuma T, Yao S, Zhu G, Flies A, Flies S, et al.

Breast cancer version 3

Author(s): Gradishar W, Anderson B, Blair S, Burstein H, Cyr A, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Author(s): Twyman-Saint VC, Rech AJ, Maity A, Rengan R, Pauken KE, et al.

Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion

Author(s): Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D

Immune cell promotion of metastasis

Author(s): Kitamura T, Qian BZ, Pollard JW

FOXP3+regulatory T cells affect the development and progression of hepatocarcinogenesis

Author(s): Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al.

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

Author(s): Dworkin AM, Spearman A, Tseng S, Sweet K, Amanda AE

Epithelial-mesenchymal transitions in development and disease

Author(s): Thiery JP, Acloque H, Huang R, Nieto A

Molecular biomarker in prostate cancer: The role of CpG island hypermethylation

Author(s): Bastian P, Yegnasubramanian S, Palapattu G, Rogers C, Lin X, et al.

Molecular epigenetics and genetics in neuro-oncology

Author(s): Nagarajan R, Costello J